MannKind Corporation (MNKD): Why Have Shares Moved?

Sanofi SA (ADR) (NYSE:SNY) is another player with a global reach that would be a good fit. The French drugmaker already has a huge moneymaker insulin with Lantus. However, Lantus goes off-patent in a few years. Sanofi SA (ADR) (NYSE:SNY) does have other diabetes products on the market and in the pipeline, but I think that an inhalable insulin would make a good addition to the lineup.

There are a number of others who could be in the midst of talks with MannKind. I’ll end my speculation for now, since it’s nothing but guessing at this point. I don’t think, though, that predicting positive results from the clinical trials for Afrezza is too speculative. Good results are likely, in my opinion.

I also think that MannKind Corporation (NASDAQ:MNKD)’s shares will enjoy upward movement as the August date for releasing those clinical results draws near. If the company happens to announce a partnership deal around the same time, then there will be plenty of buzz about a giant leap for MannKind.

The article 1 Giant Leap for MannKind originally appeared on Fool.com and is written by Keith Speights.

Fool contributor Keith Speights and The Motley Fool have no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.